期刊
NEUROTHERAPEUTICS
卷 12, 期 4, 页码 747-768出版社
SPRINGER
DOI: 10.1007/s13311-015-0375-5
关键词
Epilepsy; seizures; cannabinoids; cannabidiol; THC; cannabis
资金
- GW Pharmaceuticals
- National Institute of Mental Health [5R37MH071739]
- National Institute of Neurological Disorders and Stroke [5R01NS074785, 5R01NS024067]
Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid system, characterize the pro- and anticonvulsive effects of cannabinoids [e.g., Delta 9-tetrahydrocannabinol and cannabidiol (CBD)], and highlight scientific evidence from pre-clinical and clinical trials of cannabinoids in epilepsy. These studies suggest that CBD avoids the psychoactive effects of the endocannabinoid system to provide a well-tolerated, promising therapeutic for the treatment of seizures, while whole-plant cannabis can both contribute to and reduce seizures. Finally, we discuss results from a new multicenter, open-label study using CBD in a population with treatment-resistant epilepsy. In all, we seek to evaluate our current understanding of cannabinoids in epilepsy and guide future basic science and clinical studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据